22nd Century Group, Inc. (NYSE: XXII) Launches New Line of Research Cigarettes

Posted on

Shares of 22nd Century Group Inc. (NYSE: XXII) saw a bump in share price on Monday following news released on Friday. The company revealed that it has launched a new line of Research Cigarettes with varying levels of nicotine. Shares soared nearly 15% compared to Friday’s closing price.

The company’s new proprietary Research Cigarettes are available directly to accredited scientists, researchers, universities and governments – worldwide.

The plant biotech company, who is also a leader in tobacco harm reduction, is the only company in the world capable of producing tobacco research cigarettes with varying levels of nicotine that range from 95% less nicotine than conventional cigarettes (0.5mg/g) to 2X – 3X the nicotine content of conventional cigarettes (50mg/g).

22nd Century Group is also the name behind SPECTRUM® brand research cigarettes which are sold only to the National Institute on Drug Abuse (NIDA.)